Literature DB >> 19487373

Metformin in breast cancer: time for action.

Pamela J Goodwin, Jennifer A Ligibel, Vuk Stambolic.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19487373     DOI： 10.1200/JCO.2009.22.1630

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  75 in total

1.  Metformin impairs the growth of liver kinase B1-intact cervical cancer cells.

Authors:  Xuxian Xiao; Qiongqiong He; Changming Lu; Kaitlin D Werle; Rui-Xun Zhao; Jianfeng Chen; Ben C Davis; Rutao Cui; Jiyong Liang; Zhi-Xiang Xu
Journal:  Gynecol Oncol       Date:  2012-06-24       Impact factor: 5.482

2.  Cells lacking the fumarase tumor suppressor are protected from apoptosis through a hypoxia-inducible factor-independent, AMPK-dependent mechanism.

Authors:  Chiara Bardella; Martina Olivero; Annalisa Lorenzato; Massimo Geuna; Julie Adam; Linda O'Flaherty; Pierre Rustin; Ian Tomlinson; Patrick J Pollard; Maria Flavia Di Renzo
Journal:  Mol Cell Biol       Date:  2012-05-29       Impact factor: 4.272

Review 3.  Triple-negative breast cancer: disease entity or title of convenience?

Authors:  Lisa Carey; Eric Winer; Giuseppe Viale; David Cameron; Luca Gianni
Journal:  Nat Rev Clin Oncol       Date:  2010-09-28       Impact factor: 66.675

4.  Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer.

Authors:  Reema Wahdan-Alaswad; J Chuck Harrell; Zeying Fan; Susan M Edgerton; Bolin Liu; Ann D Thor
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

5.  Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator.

Authors:  Kuen-Haur Lee; En-Chi Hsu; Jih-Hwa Guh; Hsiao-Ching Yang; Dasheng Wang; Samuel K Kulp; Charles L Shapiro; Ching-Shih Chen
Journal:  J Biol Chem       Date:  2011-09-14       Impact factor: 5.157

6.  Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models.

Authors:  Pei Zhu; Meghan Davis; Amanda J Blackwelder; Nora Bachman; Bolin Liu; Susan Edgerton; Leonard L Williams; Ann D Thor; Xiaohe Yang
Journal:  Cancer Prev Res (Phila)       Date:  2013-12-09

7.  Metformin use and its effect on gastric cancer in patients with type 2 diabetes: A systematic review of observational studies.

Authors:  Peiwen Li; Cong Zhang; Peng Gao; Xiaowan Chen; Bin Ma; Dehao Yu; Yongxi Song; Zhenning Wang
Journal:  Oncol Lett       Date:  2017-11-08       Impact factor: 2.967

8.  Targeting myeloid-derived suppressor cells using a novel adenosine monophosphate-activated protein kinase (AMPK) activator.

Authors:  Prashant Trikha; Robert L Plews; Andrew Stiff; Shalini Gautam; Vincent Hsu; David Abood; Robert Wesolowski; Ian Landi; Xiaokui Mo; John Phay; Ching-Shih Chen; John Byrd; Michael Caligiuri; Susheela Tridandapani; William Carson
Journal:  Oncoimmunology       Date:  2016-07-25       Impact factor: 8.110

Review 9.  Effects of sulfonylureas on tumor growth: a review of the literature.

Authors:  Giulia Pasello; Loredana Urso; Pierfranco Conte; Adolfo Favaretto
Journal:  Oncologist       Date:  2013-09-16

10.  Metformin, cancer, alphabet soup, and the role of epidemiology in etiologic research.

Authors:  Bruce B Duncan; Maria I Schmidt
Journal:  Diabetes Care       Date:  2009-09       Impact factor: 19.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.